Quality of Life Effects of Alprostadil Therapy for Erectile Dysfunction

Willke, Richard J.; Glick, Henry A.; McCarron, Thomas J.; Erder, Moshe H.; Althof, Stanley E.; Linet, Otto I.

doi:10.1016/s0022-5347(01)64692-5

Cited by 70 publications

(34 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, this improvement can have a direct impact on other aspects of their lives, which are in principle independent from the sexual aspect. 39,40 Finally, this study has included with the measurement of the efficacy of ED treatment with sildenafil, the opinion of the partners of patients. It is interesting to see that there is a certain agreement between the favourable opinions given by both patients and their partners on sildenafil treatment.…”

Section: Discussionmentioning

confidence: 99%

Erectile dysfunction in a primary care setting: results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use

et al. 2001

View full text Add to dashboard Cite

In order to assess the effectiveness of sildenafil under routine conditions of use in primary care settings and to evaluate its impact on patient's life satisfaction and partner's satisfaction with treatment for erectile dysfunction (ED), an open, multicentre, observational, prospective study was designed in which 2816 patients were treated with sildenafil for at least 10 weeks. Effectiveness was assessed using the International Index of Erectile Dysfunction (IIEF), life satisfaction was measured with 'Life-satisfaction Check List' (LISAT 8), and EDITS was optionally used to assess the partner's satisfaction with ED therapy. Sildenafil was effective in 86.6% of patients. All dimensions of IIEF significantly increased with sildenafil, particularly erectile domain which overall sample mean score improved was 13.2 points (P < 0.001). The greatest increases in satisfaction with all aspects of life were seen in sex life and relationship with partner dimensions. The patients' partners, answered by a minority of partners, were highly satisfied with the treatment and its rapid action, therefore they were in favour of continuing with same. The adverse events occurring were similar to those seen in clinical research on sildenafil in the premarketing phase. No control group was included in this study.

show abstract

Section: Discussionmentioning

confidence: 99%

Erectile dysfunction in a primary care setting: results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use

et al. 2001

View full text Add to dashboard Cite

show abstract

“…2 It indicates that alprostadil therapy not only is effective in improving erectile function but also helps improve overall sexual functioning to a degree that alleviates the broader mental and social health problems that can be associated with sexual dysfunction.…”

Section: Discussionmentioning

confidence: 99%

“…1,2 For many individuals, sexual functioning may be an important factor determining psychosocial health. 3,4 Erectile dysfunction results from a variety of causes and may be treated with a growing number of therapies.…”

Section: Introductionmentioning

confidence: 99%

Quality of life effects of alprostadil therapy for erectile dysfunction: results of a trial in Europe and South Africa

et al. 1998

View full text Add to dashboard Cite

Objectives: Quality of life (QOL) data were used to evaluate the effects of self-administered intracavernosal injection of alprostadil for erectile dysfunction, when used for up to 18 months during a 13 country Phase III clinical trial. Methods: The Duke Health Pro®le was used to measure patients' physical and psychosocial QOL at baseline, 3, 6, 12 and 18 months. Changes from baseline were measured using paired t-tests, with additional analyses by cause of dysfunction, starting dosage, and prior treatment. Results: Patients displayed signi®cant improvements in mental and social health and self-esteem at six months (P`0.01, n 570), with greater improvements at 12 and 18 months. Anxiety and depression measures also improved signi®cantly at 12 and 18 months, as did the summary general health score. Worse pain scores were observed in the ®rst year but not at 18 months. Those with a starting dosage of 10±20 mg, those with psychogenic causes of dysfunction, and those with no prior treatment for erectile dysfunction generally showed the greatest improvements. Conclusion: In this study, the clinical improvements in erectile function due to intracavernosal alprostadil therapy were complemented by QOL improvements, particularly in the mental health, of many patients.

show abstract

“…2 Patients who have had non-nervesparing procedures and those who have failed oral therapy will require other options such as intracorporeal (IC) injections, vacuum constriction device (VCD) or MUSE (transurethral insertion of alprostadil (PGE1)). 1,3 In addition, MUSE is also an option for treatment of ED of neurogenic, psychogenic, arteriogenic or mixed vasculogenic causes. 3,4 A number of studies have documented the successful treatment of ED with MUSE.…”

Section: Introductionmentioning

confidence: 99%

Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis

et al. 2004

View full text Add to dashboard Cite

Baseline and follow-up data of 54 patients from a single surgical series (1998)(1999)(2000)(2001), who used medicated urethral system for erection (MUSE) for the erectile dysfunction (ED) associated with radical prostatectomy (RP), were obtained. Patients were surveyed using the abridged five-item version of the International Index of Erectile Function (IIEF) questionnaire, commonly referred to as the Sexual Health Inventory of Men (SHIM), to determine presence and severity of ED and efficacy of ED treatment modalities. The mean patient age was 63.775.6 y and the mean follow-up period was 2.371.2 y. All patients experienced ED for at least 6 months after their surgery before starting MUSE therapy. Overall, 55% of the patients achieved and maintained erections sufficient for sexual intercourse while on MUSE and 48% continued long-term therapy with a mean use of 2.3271.2 y. The mean presurgery SHIM score in these patients was 19.271.3, which decreased to 5.270.5 after surgery and increased to 16.371.3 after MUSE treatment. A total of 28 patients (52%) discontinued treatment after a mean use of 871.4 months. The reasons for discontinuation were insufficient erections (n ¼ 16, mean SHIM score of 10.574.4), switch to other ED therapies (n ¼ 4), natural return of erections (n ¼ 4) and urethral pain and burning (n ¼ 4). Excluding the patients (n ¼ 8) who preferred other therapies and return of natural erections, the compliance to MUSE was 63%. There were no significant differences in the IIEF-5 responses between the patients who had a nervesparing technique (n ¼ 34) and those who did not (n ¼ 20) or among patients who used different doses (250, 500 or 1000 lg) of MUSE. The results of the current trial indicate that MUSE is a successful treatment option in RP patients with established ED. It appears that a post-treatment SHIM score of Z16 defines a successful outcome with MUSE therapy.

show abstract

Quality of Life Effects of Alprostadil Therapy for Erectile Dysfunction

Abstract: Clinical improvements in erectile function due to alprostadil therapy were associated with improvements in sexual activity, sexual satisfaction and overall mental health.

Cited by 70 publications

References 10 publications

Erectile dysfunction in a primary care setting: results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use

Erectile dysfunction in a primary care setting: results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use

Quality of life effects of alprostadil therapy for erectile dysfunction: results of a trial in Europe and South Africa

Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis

Contact Info

Product

Resources

About